12 Best Beaten Down Stocks to Buy According to Hedge Funds

Page 10 of 12

3. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 67

52-Week Low: $42.9

Stock Price: $43.80

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Beaten Down Stocks to Buy According to Hedge Funds. On October 10, Citi lifted the price target on the company’s stock to $48 from $47, while keeping a “Neutral” rating on the stock, as reported by The Fly. Notably, the firm adjusted price targets in the biotechnology and pharmaceuticals sector as part of the Q3 earnings preview. As per the analyst, the group remains well-placed into H2 2025 and 2026 as policy overhangs ease and investor emphasis gets back to fundamentals.

Elsewhere, Bristol-Myers Squibb Company (NYSE:BMY) and Orbital Therapeutics announced a definitive agreement under which the former will acquire Orbital. The acquisition consists of Orbital’s lead RNA immunotherapy preclinical candidate, currently in IND-enabling studies, OTX-201. Also, Bristol-Myers Squibb Company (NYSE:BMY) would acquire Orbital’s proprietary RNA platform, which integrates circular and linear RNA engineering, advanced LNP delivery, and AI-driven design in a bid to enable durable, programmable RNA therapies tailored to the distinct biology of the diseases.

Page 10 of 12